Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Alendronic acid (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BLADE; BLADE-PCI
- Sponsors BIOrest
- 10 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 11 Jan 2016 New trial record